Equities research analysts at Stifel Nicolaus increased their price target on shares of Newlink Genetics Cor (NASDAQ: NLNK) to $21.00 in a research note issued to investors on Friday.

Several other analysts have also recently commented on the stock. Analysts at Robert W. Baird reiterated an “outperform” rating on shares of Newlink Genetics Cor in a research note to investors on Monday, February 11th. They now have a $20.00 price target on the stock. Analysts at MLV Capital initiated coverage on shares of Newlink Genetics Cor in a research note to investors on Thursday, January 3rd. They set a “buy” rating and a $18.50 price target on the stock.

Two analysts have rated the stock with a buy rating, and one has assigned an overweight rating to the company’s stock. Newlink Genetics Cor currently has a consensus rating of “buy” and an average price target of $18.83.

Newlink Genetics Cor traded down 0.59% on Friday, hitting $11.70. Newlink Genetics Cor has a 1-year low of $8.32 and a 1-year high of $18.00. The stock’s 50-day moving average is currently $11.97. The company’s market cap is $244.7 million.

NewLink Genetics Corporation (NewLink) is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.